Premium
DEVELOPMENT OF CARDIAC DYSFUNCTION INDUCED BY REPETITIVE TRANSIENT MYOCARDIAL ISCHAEMIA IS INHIBITED BY EDARAVONE IN CONSCIOUS RATS
Author(s) -
Toyota Eiji,
Miyamoto Yoshinori,
Imai Koichiro,
Neishi Yoji,
Kawamoto Takahiro,
Okura Hiroyuki,
Yoshida Kiyoshi
Publication year - 2009
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2009.05178.x
Subject(s) - edaravone , free radical scavenger , medicine , ventricle , ischemia , cardiology , anesthesia , oxidative stress
SUMMARY1 In the present study, we investigated the effects of treatment with the hydroxyl radical scavenger 3‐methyl‐1‐phenyl‐2‐pyrazolin‐5‐one (edaravone) on myocardial dysfunction induced by transient but frequent ischaemia in conscious rats. 2 Conscious male Wistar rats were subjected to repetitive ischaemia (RI; 40 s ischaemia every 20 min for 72 h). After the ninth episode of RI, edaravone (1 mg/kg, i.v., at each ischaemic event) or vehicle control (acetate buffer solution, i.v.) was administered. Dilation of the left ventricle (LV) after the eighth RI (fractional area change; %FAC initial ) and after the final RI (%FAC final ) was determined by comparing measurements (12 MHz echocardiogram) at these time‐points with baseline LV area prior to RI. 3 In controls, %FAC final was correlated with %FAC initial ( r = 0.98; P < 0.0001), making %FAC initial a predictor of %FAC final . Edaravone treatment shifted the %FAC initial –%FAC final relationship downward ( P < 0.0001), indicating that edaravone inhibited progression of LV dilation. In addition, %FAC final was correlated with myocardial generation of reactive oxygen species (ROS) in control samples ( r = 0.88, P = 0.008), although both %FAC final and ROS were suppressed by edaravone treatment ( P = 0.016). 4 We conclude that repetitive transient ischaemia in conscious rats induced development of cardiac dysfunction and that this phenomenon was inhibited by edaravone. We speculate that edaravone is a potential therapeutic agent that may interfere with the progression of cardiac dysfunction in high‐risk patients with RI.